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ORIGINAL RESEARCH
Dysregulation of Endothelial Nitric 
Oxide Synthase Does Not Depend on 
Hemodynamic Alterations in Bicuspid Aortic 
Valve Aortopathy
Simon Gauer , MD; Brittany Balint, PhD; Catherine Kollmann, MD; Jan M. Federspiel, BSc; Dominic Henn , MD; 
Doris Bandner-Risch, BSc; Wolfram Schmied, Dipl. Psych.; Hans-Joachim Schäfers , MD, PhD
BACKGROUND: Bicuspid aortic valves (BAVs) predispose to ascending aortic aneurysm. Turbulent blood flow and genetic fac-
tors have been proposed as underlying mechanisms. Endothelial nitric oxide synthase (eNOS) has been implicated in BAV 
aortopathy, and its expression is regulated by wall shear stress. We hypothesized that if turbulent flow induces aneurysm 
formation in patients with a BAV, regional differences in eNOS expression would be observed in BAVs.
METHODS AND RESULTS: Ascending aortic specimens were harvested intraoperatively from 48 patients with tricuspid aortic 
valve (19 dilated, 29 nondilated) and 38 with BAV (28 dilated, 10 nondilated) undergoing cardiac surgery. eNOS mRNA and 
protein concentration were analyzed at the convex and concave aortic wall. In nondilated aortas, eNOS mRNA and protein 
concentration were decreased in BAV compared with tricuspid aortic valve (all P<0.05). eNOS expression was increased in 
association with dilation in BAV aortas (P=0.03), but not in tricuspid aortic valve aortas (P=0.63). There were no regional dif-
ferences in eNOS mRNA or protein concentration in BAV aortas (all P>0.05). However, eNOS expression was increased at the 
concave wall (versus convexity) in tricuspid aortic valve dilated aortas (all P<0.05).
CONCLUSIONS: Dysregulated eNOS occurs independent of dilation in BAV aortas, suggesting a potential role for aberrantly 
regulated eNOS expression in the development of BAV-associated aneurysms. The absence of regional variations of eNOS 
expression suggests that eNOS dysregulation in BAV aortas is the result of underlying genetic factors associated with BAV 
disease, rather than changes stimulated by hemodynamic alterations. These findings provide insight into the underlying 
mechanisms of aortic dilation in patients with a BAV.
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The bicuspid aortic valve (BAV) is the most com-mon congenital cardiovascular malformation, with a prevalence of 0.5% to 2%.1–3 Of those af-
flicted, ≈50% to 60% will develop an aortic aneurysm 
during their lifetime.1,2,4–6 Compared with patients with 
a tricuspid aortic valve (TAV), BAV is associated with 
larger aortic root dimensions and a higher progression 
rate of dilation, suggesting that the pathogenesis of 
thoracic aortic dilatation associated with BAV is dif-
ferent.7,8 Turbulent flow as a result of the asymmetric 
opening of the valve in BAV has been postulated as 
an essential determinant for the development of aortic 
dilatation.5,9–11
The high incidence of dilatation in asymptomatic 
patients with BAV and the progression of aortic dilation 
after aortic valve replacement12,13 has been linked to 
intrinsic changes within the aortic wall, offering an al-
ternate theory for the development of BAV-associated 
thoracic aortic dilatation. Compared with patients 
with a TAV, medial changes such as thinning and 
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fragmentation of elastic lamellae, loose attachments 
of vascular smooth muscle cells to their surrounding 
lamellae and precocious vascular smooth muscle cell 
apoptosis and senescence have been found in BAV 
aortas.14–20 These changes to the aortic wall indicate 
an inherent structural defect that is not observed in 
TAV aortas and may therefore be the result of genetic 
influences associated with BAV.
There is evidence to suggest that endothelial ni-
tric oxide (NO) synthase (eNOS) may be a potential 
contributor to BAV development. Using animal mod-
els, Lee and colleagues21 observed BAV morphology 
in 5 of 12 eNOS knockout mice. Furthermore, stud-
ies of human aortopathy showed that eNOS ex-
pression is altered in the thoracic aortic wall of BAV 
patients compared with patients with a TAV.22–24 It 
is unclear, however, whether these changes in the 
eNOS system are genetically determined or if they 
are the consequence of turbulent flow and altered 
wall stress.
Magnetic resonance imaging in patients with a BAV 
has clearly indicated that blood flow patterns and sub-
sequent aortic wall shear stress are altered in patients 
with a BAV compared with a TAV.9,25 Furthermore, aor-
tic wall shear stress in patients with a BAV appears to 
depend also on the cusp fusion morphology, with the 
most common fusion pattern (right and left coronary 
cusp fusion [R-L]) displaying increased shear stress 
in the convex wall of the proximal and mid-ascending 
aorta.26,27 However, whether this change in wall shear 
stress is the primary mechanism of aortic dilatation in 
patients with a BAV remains unknown.28 To determine 
if eNOS expression is influenced by turbulent flow in 
BAV aortas, we analyzed the mRNA expression and 
protein levels of eNOS at various regions within BAV 
aortas.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon rea-
sonable request. This prospective study was con-
ducted in accordance with the Declaration of Helsinki 
and was approved by the locally appointed Ethics 
Committee (Ethikkommission bei der Ärztekammer 
des Saarlandes, No. 205/10). All patients gave written 
informed consent.
Samples
We collected samples of ascending aortic tissue 
from 86 patients undergoing aortic valve reconstruc-
tion or replacement, with or without ascending aor-
tic replacement. The samples were extracted at the 
convexity and concavity of the ascending aorta, 5 to 
10 mm cranial to the sinotubular junction and from 
the midascending aorta (Figure 1). Transesophageal 
echocardiography was used to characterize aortic 
dimensions, and aortic valve morphology was deter-
mined intraoperatively. Tissue samples were imme-
diately snap frozen in liquid nitrogen and stored at 
−80°C. If sinus or tubular ascending aortic diameter 
were >40 mm, the ascending aorta was considered 
dilated. BAV was present in 38 patients, and TAV was 
present in 48 patients. The distribution of valve mor-
phology and aortic dilatation of the patients are sum-




• Herein, we report changes in the mRNA ex-
pression and protein concentration of endothe-
lial nitric oxide synthase in the ascending aorta 
of patients with a bicuspid aortic valve (BAV) 
compared with patients with a tricuspid aortic 
valve.
• The mRNA and protein levels of endothelial ni-
tric oxide synthase in the aorta are not impacted 
by hemodynamic alterations associated with 
BAVs.
• The mRNA expression of endothelial nitric oxide 
synthase is increased in the concave wall of the 
aorta in patients with a tricuspid aortic valve.
What Are the Clinical Implications?
• The bicuspid aortic valve is the most common 
cardiovascular malformation, and it is associ-
ated with a strong predilection for ascending 
aortic aneurysm.
• Although hemodynamic alterations are asso-
ciated with the BAV, our findings suggest that 
ascending aortic dilation in patients with a BAV 
occurs independently of turbulent flow patterns.
• Our discovery of regionally variable eNOS ex-
pression in tricuspid aortic valve aortas prompts 
further research into the role of molecular bio-
logic patterns in aortic remodeling.
Nonstandard Abbreviations and Acronyms
BAV bicuspid aortic valve
eNOS endothelial nitric oxide synthase
HMBS hydroxymethylbilane synthase
R-L right and left coronary cusp fusion
TAV tricuspid aortic valve
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RNA Isolation and Complementary DNA 
Synthesis
RNA isolation was performed with the mirVana PARIS 
Kit (Ambion, Austin, TX). Frozen tissue samples were 
homogenized using an Ultra Turrax T8 homogenizer 
(Ika, Staufen, Germany) and an ultrasonic proces-
sor UP100H (Hielscher, Teltow, Germany). Further 
isolation was performed according to the manu-
facturer’s recommendations. DNAse digestion and 
RNA cleanup were done with the RNeasy Mini Kit 
(Qiagen, Hilden, Germany). RNA quantity and qual-
ity were determined with an Infinite 200 NanoQuant 
(Tecan, Mannedorf, Switzerland). RNA integrity was 
confirmed with an Agilent 2100 Bioanalyzer and the 
Agilent 6000 Nano Kit (Agilent Technologies, Santa 
Clara, CA). Reverse transcription was performed 
using the High Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Foster City, CA) according 
to the manufacturer’s recommendations. Quantitative 
real-time polymerase chain reaction was performed 
with TaqMan Gene Expression Assays (Applied 
Biosystems) nitric oxide synthase 3 (Hs01574659_
m1) on 96-well TaqMan Plates (Applied Biosystems). 
The plates were run in a StepOnePlus Real Time 
PCR System (Applied Biosystems). Each well con-
tained 20 ng of complementary DNA and had a total 
reaction volume of 10 mL, consisting of 5 mL com-
plementary DNA diluted with diethylpyrocarbonate-
treated water and 5  mL TaqMan Gene Expression 
MasterMix (Applied Biosystems). All samples were 
run as triplicates. The gene expression levels of ni-
tric oxide synthase 3 in patients with a BAV were de-
termined relative to the expression levels in samples 
from patients with TAV without aortic dilatation using 
eukaryotic transcription initiation factor 2B, subunit 
1, ets-related transcription factor 1, and hydroxym-
ethylbilane synthase as internal control genes. These 
genes have been identified as reference genes for 
expression analyses on aortic tissue from patients 
with different valve morphologies in previous stud-
ies.23 The expression level of nondilated TAV samples 
was set as 1. For comparisons between convex and 
concave regions of the aorta, relative expression of 
Figure 1. Schematic representation of the human aorta, 
with tissue sampling sites indicated.
To assess for endothelial nitric oxide synthase (eNOS) mRNA 
expression and protein concentration in the ascending aorta 
of patients with a bicuspid aortic valve, tissue samples were 
harvested from the convex and concave walls of the aorta, 
adjacent to the sinotubular junction (STJ) and at the level of the 
mid-ascending aorta. Samples from patients with a tricuspid 
aortic valve were used as comparison. Sample sites are indicated 
by rectangular boxes: samples of convex wall (A1) and concave 
wall (A2) adjacent to the STJ and samples of convex (B1) and 
concave wall (B2) from the mid-ascending aorta were harvested. 
This schematic representation indicates a bicuspid aortic valve, 











Age, y 63.9±13.6 54.7±15.1
Sex, male, % 68.8 92.1
Aortic valve pathology, n (%)
Stenosis 13 (27.1) 29 (76.3)
Insufficiency 27 (56.3) 3 (7.9)
Combined 8 (16.7) 6 (15.8)
Comorbidities, n (%)
Hypertension 29 (60.4) 12 (31.6)
Diabetes mellitus 2 (4.2) 0
Hyperlipidemia 7 (14.6) 7 (18.4)
Coronary artery disease 14 (29.2) 2 (5.3)
Medication, n (%)
ß-Blocker 20 (41.7) 17 (44.7
Angiotensin-converting enzyme inhibitor 19 (39.6) 14 (36.8)
Angiotensin 1-receptor antagonist 7 (14.6) 5 (13.2)
Diuretic 14 (29.2) 13 (34.2)
Insulin 3 (6.3) 0
Calcium channel blocker 10 (20.8) 3 (7.9)
Statin 15 (31.3) 7 (18.4)
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nitric oxide synthase 3 normalized to the reference 
genes was compared within each patient, and mean 
differences were compared within groups. Relative 
quantification values for nitric oxide synthase 3 were 
determined with the 2–DDCT method.
Protein Quantification
Samples were lysed by mechanical force and the 
protein portion was isolated by using Protein Quant 
Sample Lysis Kit (Life Technologies, Rockville, 
MD). To determine the protein content within the 
lysate, Micro BCA Protein Assay (Thermo Scientific, 
Waltham, MA) was performed. The tissue lysates 
were then stored at −80°C for further examination at 
a later date. Protein expression of eNOS was ascer-
tained by western blot analysis. The samples were 
diluted with Roti Load 1 (Carl Roth GmbH, Karlsruhe, 
Germany) and loaded onto polyacrylamide Bis-Tris 4 
to 12% gels (Life Technologies). After separation of 
the protein fractions by electrophoresis, the samples 
were blotted onto Roti-PVDF transfer membranes 
(Carl Roth GmbH) and blocked with phosphate-
buffered saline/milk powder 5% for 1 hour at room 
temperature. The membranes were then incubated 
with primary antibodies against eNOS (Anti-eNOS/
NOS Type III Mouse, 1:1.000; BD Transduction 
Laboratories, Franklin Lakes, NJ) and β-actin (β-Actin 
8H10D10 Mouse mAB, 1:200.000; Cell Signaling 
Technology, Danvers, MA) at 4°C overnight. After 
washing the membranes with phosphate-buffered 
saline +/- Tween20, an incubation with a second-
ary antibody (Peroxidase-conjugated AffiniPure Goat 
Anti-Mouse IgG, 1:1.000; Jackson ImmunoResearch, 
West Grove, PA) was executed for 1  hour at room 
temperature. Chemiluminescent staining (Pierce ECL 
Western Blotting Substrate, Thermo Scientific) was 
used for detection of the crucial protein bands. All 
eNOS bands were evaluated as a relative quantity 
subject to the respective β-Actin bands within the 
same line. For comparisons between convex and 
concave regions of the aorta, relative eNOS concen-
tration (eNOS/β-actin) was compared between the 
convexity and the concavity within each patient, and 
mean differences were compared within groups.
Statistical Analysis
Data analysis was performed using SPSS Statistics 
19 software (IBM, Ehningen, Germany). We analyzed 
eNOS expression in the ascending aortic wall and the 
aortic diameter by the Pearson product moment cor-
relation coefficient or the Spearman correlation when 
data were not normally distributed. All data sets were 
tested for normality by the D’Agostino and Pearson 
omnibus test. In the case of normally distributed dis-
tributions, comparisons were made by the Student t-
test. Nonparametric distributions were compared by 
the Whitney U-test.
RESULTS
Endothelial Nitric Oxide Synthase 
Expression Is Altered in the Aorta From 
Patients With a Bicuspid Aortic Valve 
Compared With Patients With a Tricuspid 
Aortic Valve
Ascending aortic tissue was harvested from a total 
of 86 patients. Aortic samples were characterized 
into four groups according to valve morphology and 
ascending aortic diameter: TAV-nondilated (n  =  29), 
TAV-dilated (n = 19), BAV-nondilated (n = 10) and BAV-
dilated (n = 28). Clinical information for all patients is 
presented in Tables 1 and 2.
Table 2. Patient Characteristics Based on Aortic Dimensions
TAV Normal TAV Dilated BAV Normal BAV Dilated
n = 29 n = 19 n = 10 n = 28
Age 66.7±7.2 59.7±5.4 59.4±4.7 52.9±8.3
Sex (M/F) 18/11 16/3 08/2 26/1
Maximal aortic diameter (cm)
Mean 3.2±0.8 5.3±1.1 3.6±0.24 4.7±0.48
Standard error ±0.8 ±1.1 ±0.24 ±0.48
Range 2.4–3.9 4.2–8.1 3.2–3.9 4.0–5.3
Ejection fraction 54.4±2.4 63.2±2.4 56.7±5.8 58.5±2.2
Gradient over aortic valve
Mean, mm Hg 21.2±3.9 5.0±0.6 13.6±5.1 10.0±2.0
Peak, mm Hg 35.0±5.7 9.5±1.1 24.6±8.3 16.8±3.1
LVOT diameter, cm 2.34±0.1 2.7±0.1 2.5±0.1 3.0±0.1
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Previous studies have shown that eNOS is ab-
errantly expressed in BAV-associated aortas com-
pared with TAV-associated aortas.23 To confirm a 
role for aberrant eNOS expression in BAV aortopathy 
in our study population, we assessed for the gene 
and protein expression of eNOS in normal and di-
lated aortas from patients with a TAV or with a BAV. 
In the absence of pathological dilation, eNOS mRNA 
Figure 2. Schematic summary of endothelial nitric oxide synthase (eNOS) expression in normal 
and dilated aortas associated with tricuspid and bicuspid aortic valves.
A, Schematic representation of a normal (nondilated) aorta associated with a tricuspid aortic valve (TAV). 
eNOS expression is relatively high (green shading) in both the convex and concave walls of the aorta. B, 
Schematic representation of a dilated aorta associated with a TAV. eNOS expression is relatively high in 
the concave wall, with decreased expression (darker green) in the convex wall of the aorta. C, Schematic 
representation of a nondilated aorta associated with a bicuspid aortic valve (BAV). eNOS expression is 
relatively low (red shading) in both the convex and concave walls. D, Schematic representation of a dilated 
aorta associated with a BAV. eNOS expression is relatively lower than in nondilated BAV aortas (darker red 
shading) and similar to that of dilated TAV aortas in the convex wall (dark shading), Within the BAV dilated 
aorta, eNOS is equally expressed between concave and convex walls.
TAV, Normal TAV, Dilated
Low                             High
eNOS Expression
A B
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expression was significantly decreased in the aor-
tas of patients with a BAV (1.11±0.04) compared with 
those with a TAV (1.31±0.06, P=0.02; Figure 2A, 2C, 
and 3A). Furthermore, eNOS protein concentration 
was decreased by 2.5-fold in BAV nondilated aor-
tas compared with TAV nondilated aortas (P=0.02; 
Figure 3B). This finding indicates a potential role for 
aberrantly regulated eNOS expression in the devel-
opment of aneurysms, specific to those associated 
with BAVs. On the other hand, when comparing 
dilated aortas from patients with a BAV and patients 
with a TAV, we found that there was no significant 
difference in eNOS mRNA expression between TAV 
(1.35±0.10) and BAV aortas (1.28±0.08; P=0.90; 
Figure 2B, 2D, and 3C). Similarly, there was no sig-
nificant difference in protein concentration between 
TAV and BAV dilated aortas (P=0.13). This further im-
plies that aberrant eNOS expression in BAV aortas 
may precede aneurysm development and is there-
fore a feature of BAV aortopathy.
Figure 3. Endothelial nitric oxide synthase (eNOS) expression is altered in bicuspid aortic valve 
(BAV) nondilated aortas compared with tricuspid aortic valve (TAV) nondilated aortas.
A, Graph depicting the eNOS mRNA expression in nondilated (normal) aortas from patients with a TAV or 
a BAV. B, Graph and corresponding western blot image depicting the eNOS protein expression in normal 
aortas from patients with a TAV and patients with a BAV. eNOS protein expression values are normalized 
to beta-actin protein expression. C, Graph depicting the eNOS mRNA expression in dilated aortas from 
patients with a TAV or BAV. D, Graph and corresponding western blot image depicting the eNOS protein 
expression in dilated aortas from patients with a TAV and patients with a BAV. eNOS protein expression 
values are normalized to beta-actin protein expression. *=significance at P<0.05; AU indicates arbitrary 
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eNOS Expression Alterations Are 
Exacerbated in Response to Dilation in 
Patients With a BAV But Not in Patients 
With a TAV
As eNOS expression is altered in BAV nondilated 
aortas, we next sought to determine whether this 
finding is exacerbated in the presence of dilation. In 
patients with a TAV, we found no significant changes 
between nondilated and dilated aortas in either 
mRNA expression (P=0.63; Figure  4A) or protein 
concentration (P=0.73; Figure  2A, 2B, and 4B) of 
eNOS. Remarkably, we found similar results for gene 
expression in patients with a BAV, as eNOS mRNA 
expression did not change in the presence of dilation 
(P=0.79; Figure  4C). This was also the case when 
comparing patients with similar BAV configurations, 
in that there was no difference in eNOS expression 
Figure 4. Endothelial nitric oxide synthase (eNOS) expression in the aorta is altered in response 
to dilation in patients with a bicuspid aortic valve (BAV) but not patients with a tricuspid aortic 
valve (TAV).
A, Graph depicting the eNOS mRNA expression in patients with a TAV with nondilated (normal) and 
dilated aortas. B, Graph and corresponding western blot image depicting the eNOS protein expression 
in normal and dilated aortas from patients with a TAV. eNOS protein expression values are normalized 
to beta-actin protein expression. C, Graph depicting the eNOS mRNA expression in normal and dilated 
aortas from patients with a BAV. D, Graph and corresponding western blot image depicting the eNOS 
protein expression in normal and dilated aortas from patients with a BAV. eNOS protein expression values 
are normalized to beta-actin protein expression. *=significance at P<0.05; AU indicates arbitrary units. 
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Figure 5. Endothelial nitric oxide synthase (eNOS) expression is altered at the concavity of the 
aortic wall compared with the convexity in dilated tricuspid aortic valve (TAV) aortas.
Graphs depicting the endothelial nitric oxide synthase (eNOS) mRNA expression (left) and protein 
expression (right) in nondilated (normal) aortas (A) and dilated aortas (B) from patients with a TAV. 
eNOS expression is compared between the convex and the concave wall of the aorta at the level of the 
sinotubular junction (STJ). C, Graphs depicting the eNOS mRNA expression (left) and protein expression 
(right) in dilated aortas from patients with a TAV. eNOS expression is compared between the convex and 
the concave wall of the aorta at the level of the mid-ascending aorta (Asc. Ao.). *=significance at P<0.05; 




 http://ahajournals.org by on February 1, 2021
J Am Heart Assoc. 2020;9:e016471. DOI: 10.1161/JAHA.120.016471 9
Gauer et al eNOS is Not Regionally Different in BAV Aortopathy
between nondilated and dilated aortas from patients 
with an R-L BAV (P=0.55) or from patients with a right 
and noncoronary cusp fusion BAV (P=0.61). However, 
there was a significant increase in eNOS protein ex-
pression in dilated aortas compared with nondilated 
aortas in the presence of a BAV (25.92±3.35 versus 
16.87±5.07, respectively; P=0.04; Figure 2C, 2D, and 
4D). This increased concentration was maintained 
when evaluating patients with an R-L BAV (P=0.04), 
and a trend for increased eNOS concentration was 
observed in dilated aortas in patients with a right and 
noncoronary cusp fusion BAV (P=0.08).
There Are No Regional Differences in 
eNOS Expression in BAV-Associated 
Aortas
To test the hypothesis that altered blood flow pat-
terns associated with a BAV-induced regional dif-
ferences in aortic wall remodeling and consequent 
dilation, we assessed for eNOS expression at various 
regions of the aortic wall in both patients with a TAV 
and patients with a BAV. In patients with a TAV and a 
nondilated aorta, we found no significant difference 
in either eNOS mRNA expression or protein concen-
tration between the convexity (outer curvature) and 
the concavity (inner curvature) of the aortic wall at the 
level of the sinotubular junction (P=0.92 and P=0.52, 
respectively; Figures  2A, 5A). Interestingly however, 
in dilated aortas from patients with a TAV, there was 
a significantly increased expression of eNOS mRNA 
in the concavity of the proximal aorta adjacent to the 
sinotubular junction compared with the convex wall 
(P=0.002; Figures  2B, 5B). Similarly, eNOS mRNA 
was significantly increased at the concavity com-
pared with the convexity of the mid-ascending aorta 
(convexity, 2.44±0.54 versus concavity, 4.02±0.36; 
P=0.003; Figure 5C) in TAV-associated dilated aortas. 
However, no significant changes in protein concentra-
tion were observed in TAV dilated aortas between the 
convexity and concavity at either the sinotubular junc-
tion (P> 0.99; Figure 5C) or the mid-ascending aorta 
(P=0.7; Figure 5D).
Although changes to blood flow and wall shear 
stress in the presence of a BAV have been well de-
scribed,27 we did not observe any regional difference 
in eNOS expression in BAV-associated dilated aor-
tas. Namely, there were no changes in eNOS mRNA 
expression or protein concentration between the 
convexity and concavity at the sinotubular junction 
of dilated BAV aortas (P=0.71 and P=0.57, respec-
tively; Figures 2C, 6A) or at the mid-ascending aorta 
of BAV-associated dilated aortas (P=0.7 and P=0.51, 
respectively; Figures 2D, 6B). Finally, we assessed for 
differences in eNOS expression between patients with 
a BAV with different cusp fusion morphologies. At the 
level of the sinotubular junction, there was no significant 
difference in eNOS expression at either the convex-
ity (P=0.44) or the concavity (P=0.47) when compar-
ing patients with an R-L BAV and patients with a right 
and noncoronary sinus BAV (Figure 6C). Furthermore, 
there was no significant difference in eNOS expression 
at the level of the mid-ascending aorta between pa-
tients with a BAV with an R-L and a right and noncor-
onary cusp fusion BAV (convexity, P=0.65, concavity, 
P=0.46; Figure 6C).
DISCUSSION
BAV is associated with dilation of the ascending aorta, 
though the underlying mechanisms are incompletely 
understood. Although valve-related hemodynamics 
may play a role, there is evidence suggesting that ge-
netic abnormalities underlie both the development of 
the BAV and the associated aortic degeneration. In 
this study, we showed that alterations in eNOS expres-
sion and concentration occur independent of patho-
logical dilation of the BAV aorta. Furthermore, eNOS 
expression remains unchanged throughout the BAV 
aortic wall, including at regions that are susceptible to 
changes in shear stress. These findings emphasize a 
genetic component as the underlying cause of aortic 
dilation in patients with a BAV.
In support of the hemodynamics theory for aortic 
dilation in patients with a BAV, several studies have 
provided evidence for regional differences in the de-
gree of pathological remodeling in BAV aortas. For 
instance, the expression of matrix metalloprotein-
ases29 and senescence markers20 were increased in 
regions susceptible to increased wall shear stress in 
BAV aortas. However, these parameters were not re-
gionally assessed in the aorta of patients with a TAV, 
so whether these findings are BAV specific remains 
unknown. Furthermore, regional differences were 
observed in extracellular matrix protein expression 
in BAV aortas, but similar findings were observed 
in the aorta of patients with Marfan syndrome with 
a TAV,30 suggesting that these findings may not be 
exclusive to BAV aortas. These results led us to 
question whether hemodynamic alterations under-
lie aortic dilation in patients with a BAV or whether 
they simply exacerbate genetically influenced aortic 
remodeling.
Although dysregulated eNOS has been impli-
cated in BAV aortopathy, the specific role of eNOS 
in aortic dilation is unclear. This could be because 
most groups have studied only mRNA expression or 
protein concentration of eNOS in the aorta, which 
yielded inconsistent findings. For example, studies by 
Henn et al23 and Kotlarczyk et al31 showed increased 
eNOS mRNA expression and activation in BAV aor-
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by Mohamed et al24 and Aicher et al22 showed a de-
crease in eNOS protein concentrations in dilated BAV 
aortas compared with dilated TAV aortas. In light of 
these inconsistent findings, we chose to study both 
the mRNA expression and the protein concentration 
of eNOS in the aorta.
In this study, we observed a significant decrease in 
both eNOS mRNA expression and protein concentration 
Figure 6. There are no regional differences in endothelial nitric oxide synthase (eNOS) expression 
in the aortic wall in dilated bicuspid aortic valve (BAV) aortas.
A-B, Graphs depicting the eNOS mRNA expression (left) and protein expression (right) in dilated aortas 
from patients with a BAV. eNOS expression is compared between the convex and the concave wall of the 
aorta at the level of (A) the sinotubular junction (STJ) and (B) the mid-ascending aorta. C, Graphs depicting 
eNOS mRNA expression between BAV aortas with right and left coronary cusp (R-L) fusions and right 
noncoronary cusp (R-N) fusions at the convexity and the concavity from the sinotubular junction (STJ) and 
the mid-ascending aorta (Asc. Ao.) in BAV aortas. *=significance at P<0.05; AU indicates arbitrary units. 
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in nondilated BAV aortas compared with normal TAV 
aortas. This implies that dysregulation of eNOS occurs 
independent of pathological dilation in BAV aortas. 
Reduced eNOS expression may have implications in 
aortic degeneration, as reduced eNOS was shown in 
association with increased matrix metalloproteinase 2 
and decreased collagen content in buckled arteries.32 
Interestingly, this difference in eNOS concentration be-
tween patient groups disappears in the case of aor-
tic dilation, as eNOS protein levels increase in dilated 
BAV aortas compared with nondilated BAV aortas. This 
could indicate a secondary role for aortic remodeling 
in further influencing eNOS regulation in BAV aortas. 
This finding is inconsistent with the results by Aicher 
et al,22 which showed that eNOS levels are negatively 
correlated with aortic diameter in patients with a BAV. 
However, there were only 5 patients with a BAV with a 
dilated aorta included in this study, and 80% of these 
patients had eNOS levels above the trendline in the cor-
relation analysis, effectively implying increased eNOS 
levels in the case of dilation. Taken together, our results 
reveal evidence for a relationship between eNOS dys-
regulation and the initiation of aortic dilation in patients 
with a BAV that may be further influenced by aortic 
remodeling.
Studies have shown that eNOS expression is regu-
lated by wall shear stress.28 Therefore, if aortic dilation 
in patients with a BAV is primarily attributable to altered 
hemodynamics, we would expect the most pronounced 
changes in eNOS expression to occur at regions of al-
tered shear stress. Although prior studies have shown 
regional differences in wall shear stress in the aorta of 
patients with a BAV,9,25 which is further influenced by 
BAV fusion type,26,27 we did not detect any correspond-
ing regional differences in eNOS mRNA expression or 
protein concentration in BAV aortas, independent of 
cusp fusion pattern. These results are in contrast to 
findings in other diseases impacting the aorta, includ-
ing atherosclerosis, where eNOS mRNA expression 
and protein concentration are reduced in atherosclerot-
ic-susceptible regions of increased wall shear stress in 
mouse and human arteries.33,34 Therefore, it is plausible 
that dysregulated eNOS expression in BAV aortas oc-
curs independent of hemodynamic alterations, and is 
likely attributable to underlying genetic factors that over-
ride flow-induced expression patterns.
As expected, we did not detect any regional dif-
ferences in eNOS expression in normal TAV aortas. 
Interestingly however, eNOS mRNA expression was sig-
nificantly decreased at the convexity of TAV dilated aor-
tas. There is limited data on hemodynamic alterations 
associated with dilated TAV aortas, but an abnormal 
helical flow pattern was observed in a group of patients 
with a TAV with a dilated ascending aorta.10 Although 
this helical flow pattern does not appear to preferentially 
direct flow toward the convexity of the aorta, it provides 
evidence for aneurysm-associated hemodynamic al-
terations that are not dependent on the presence of 
a BAV. In fact, helical flow patterns in the ascending 
aorta may be linked to pressure changes across the 
left ventricular outflow tract, which occur when the ge-
ometry between the left ventricular outflow tract and 
the ascending aorta is distorted.35 This angular change 
between the left ventricular outflow tract and the aorta 
can occur with diseases of the aortic valve,36 but also 
as a result of ascending aortic elongation, which oc-
curs in response to aging.37 Interestingly, a recent study 
showed that aortic elongation is associated with an 
increased prevalence of aortic adverse events,38 most 
likely linked to the observation that aortic dilatation con-
curs with elongation. Further work is needed to define 
clearly if the mechanisms of aortic elongation are iden-
tical to those of aortic dilatation, and if aortic elongation 
contributes to the regional differences in eNOS transcript 
expression observed in TAV-associated aneurysms.
In summary, the current work confirms the involve-
ment of dysregulated eNOS in BAV-associated aortop-
athy. However, since eNOS expression is not regionally 
variable in BAV aortas, it is likely that dysregulated 
eNOS in BAV aortopathy is the result of genetic fac-
tors associated with the disease, rather than changes 
stimulated by hemodynamic alterations. Furthermore, 
the interesting finding of regionally variable eNOS tran-
script expression in TAV-associated dilated aortas 
prompts further research into the possible relationship 
between ascending aortic elongation, associated he-
modynamic alterations, and aortic wall remodeling, re-
gardless of disease background.
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